Feasibility of adjuvant chemotherapy with doxorubicin plus docetaxel followed by sequential capecitabine in patients with node positive breast cancer.

被引：0
|
作者：
Lara, R
Mayordomo, JI
Modolell, A
Burillo, M
Sanz, J
Murillo, L
Janariz, J
Perez, V
Andres, R
Tres, A
机构：
[1] Hosp Clin Univ, Zaragoza, Spain
[2] Inst Oncol Corachan, Barcelona, Spain
[3] Hosp San Jorge, Huesca, Spain
[4] Hosp Tudela, Tudela, Spain
[5] Hosp Creu Roja De Barcelona, Barcelona, Spain
[6] Hosp Arritxaca, Murcia, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
782
引用
收藏
页码：72S / 72S
页数：1
相关论文
共 50 条
  • [41] Adjuvant sequential docetaxel and cyclophosphamide-doxorubicin combination in operable breast cancer patients.
    Coskun, HS
    Er, O
    Ozkan, M
    Eser, B
    Altinbas, M
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 82S - 82S
  • [42] A phase II study of capecitabine and weekly docetaxel combination chemotherapy in patients with metastatic breast cancer.
    Puglisi, F
    Scalone, S
    Minisini, AM
    Mansutti, M
    Crivellari, D
    Buonadonna, A
    Zanetti, M
    Ermacora, P
    Piga, A
    Veronesi, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 78S - 78S
  • [43] Preoperative sequential chemotherapy of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine in patients with stage II/IIIA breast cancer
    Grassadonia, A.
    Cianchetti, E.
    Ficorella, C.
    Angelucci, D.
    Grossi, S.
    Ricevuto, E.
    Zilli, M.
    Tinari, N.
    Natoli, C.
    Iacobelli, S.
    BREAST, 2007, 16 : S48 - S48
  • [44] Primary chemotherapy with sequential docetaxel followed by docetaxel and epirubicin in large operable breast cancer
    Frutuoso, C.
    Henriques, I.
    Pazos, I.
    Abraul, E.
    Pego, A.
    Belo, J.
    Campos, O.
    Gervasio, H.
    De Oliveira, C.
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2007, 28 (06) : 447 - 450
  • [45] A multicenter randomized study comparing the dose dense G-CSF-supported sequential administration of FEC followed by docetaxel versus paclitaxel as adjuvant chemotherapy in women with axillary lymph node positive breast cancer.
    Mavroudis, D.
    Malamos, N.
    Boukovinas, I.
    Kakolyris, S.
    Kourousis, C.
    Athanasiadis, A.
    Ziras, N.
    Makrantonakis, P.
    Polyzos, A.
    Christophylakis, C.
    Georgoulias, V.
    CANCER RESEARCH, 2012, 72
  • [46] Randomized phase III trial comparing the sequential administration of docetaxel followed by epirubicin plus cyclophosphamide versus FE75C as adjuvant chemotherapy in axillary lymph node-positive breast cancer
    Mavroudis, D.
    Malamos, N.
    Papakotoulas, P.
    Adamou, A.
    Christophyllakis, C.
    Ziras, N.
    Syrigos, K.
    Kakolyris, S.
    Kouroussis, C.
    Georgoulias, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Overall Survival Benefit for Sequential Doxorubicin-Docetaxel Compared to Concomitant Doxorubicin and Docetaxel in Node-Positive Breast Cancer. 8-Yr. Results of the Breast International Group (BIG) 2-98 Phase III Adjuvant Trial
    Di Leo, A.
    Francis, P.
    Crown, J. P.
    de Azambuja, E.
    Quinaux, E.
    Gutierrez, J.
    Nordenskjold, B.
    Andersson, M.
    Margeli, Vila M.
    Piccart-Gebhart, M.
    Jakesz, R.
    Viale, G.
    Olsen, S. R.
    CANCER RESEARCH, 2009, 69 (24) : 521S - 521S
  • [48] Adjuvant CMF in node positive breast cancer.: Analysis of 173 patients.
    Valentí, V
    Borràs, JL
    Lainez, N
    Rubió, J
    Creus, J
    Anglada, L
    Villar, JL
    Pelegrí, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S58 - S58
  • [49] A randomized phase II trial of doxorubicin plus pemetrexed followed by docetaxel versus doxorubicin plus cyclophosphamide followed by docetaxel as neoadjuvant treatment of early breast cancer
    Schneeweiss, A.
    Marme, F.
    Ruiz, A.
    Manikhas, A. G.
    Bottini, A.
    Wolf, M.
    Sinn, H. -P.
    Mansouri, K.
    Kennedy, L.
    Bauknecht, T.
    ANNALS OF ONCOLOGY, 2011, 22 (03) : 609 - 617
  • [50] Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer
    Yago Nieto
    José Manuel Aramendía
    Jaime Espinós
    Susana De la Cruz
    Oscar Fernández-Hidalgo
    Marta Santisteban
    Leyre Arbea
    Javier Aristu
    Rafael Martínez-Monge
    Marta Moreno
    Luis Pina
    Josu Sola
    Gerardo Zornoza
    Fernando Martínez Regueira
    Cancer Chemotherapy and Pharmacology, 2010, 65 : 457 - 465
12345